Ultime notizie per CBD Life Sciences (OTC:CBDL) Azioni

CBD Life Sciences Inc is developing and marketing a line of cannabidiol-based organic products such as hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a full line of pet products.

CBD LIFE SCIENCES INC by CBD Life Sciences Inc.

CBD Life Sciences Inc

Dan Morehead, founder and CEO of Pantera Capital on Friday said <a href="https://www.benzinga.com/25/05/45560419/trumps-crypto-czar-david-sacks-foresees-stablecoin-bill-generating-trillions-for-us-treasury-practically-overnigh">the crypto industry</a> is poised to see a surge of public offerings, with companies like Circle (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) and Figure among those preparing to go public in the coming months.
What Happened: His <a href="https://www.cnbc.com/video/2025/05/21/pantera-capital-ceo-expects-wave-of-crypto-companies-to-go-public-in-next-6-months.html">comments</a> come amid what he described as a "flipping" of the U.S. regulatory environment, from a hostile stance to one that is now either "positive or at least neutral."
Morehead attributed this shift to multiple policy developments, including the SEC's rollback of Staff Accounting Bulletin 121, and new OCC guidance enabling banks to interact more directly with blockchain infrastructure. 
Combined, he said, these actions are unlocking long-constrained potential. 
"There are a lot of great companies that maybe should have gone public a few years ago," Morehead said. "In the next six months you're going to see a wave of great companies like Circle and Figure go public."
The renewed interest in U.S. capital markets for crypto is further underscored by strong demand from public investors. 
"MicroStrategy and other coin-based stocks prove people really want to invest in blockchain companies," he added.
Morehead emphasized this is not a short-term spike, but rather the beginning of a broader trend. 
"All of these companies have been kind of stuck in the pipe for the last two or three years," he said. "Now that they&#8217;re going public and each are going public today, it's trading up 35%, encourages other companies to go public. So I think it&#8217;s a big new trend."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45572374/xrp-dogecoin-shiba-inu-waiting-to-pump-they-dominate-mindshare-they-can-lead-in-culture-expert-says">XRP, Dogecoin, Shiba Inu Waiting To Pump: &#8216;They Dominate Mindshare, They Can Lead In Culture,&#8217; Expert Says</a>
Why It Matters: Pantera's optimism also stems from the rise of real-world assets on the blockchain, particularly in areas like stablecoins, tokenized treasuries, and on-chain mortgages.
He pointed to Pantera-backed projects such as Ondo Finance (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ONDO</a>) and Figure, noting that Figure has already issued $40 billion worth of mortgages on blockchain rails, shaving off "over 100 basis points of friction."
When asked what further developments are needed to accelerate industry growth, Morehead highlighted regulatory clarity. 
"Uncertainty in the U.S. has driven innovation offshore," he said, noting that many companies previously relocated to jurisdictions like Singapore and the UAE due to hostility at home.
With the U.S. now appearing more open to blockchain innovation, he expects talent and capital to flow back.
Pantera is also actively participating in policy conversations in Washington, according to Morehead. "We're involved in a couple industry think tanks that advise the government. It's very important that blockchain happens in the U.S. rather than offshore."
As more companies up-list from international exchanges such as the TSX to U.S. markets, Morehead views this as a reversal of previous trends. "The U.S. has really been unique. Most countries have been neutral. Now the U.S. is going from being antagonistic to positive, and that helps people want a base in the U.S."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45571765/kraken-to-launch-247-tokenized-stock-trading-for-global-users-via-solana">Kraken To Launch 24/7 Tokenized Stock Trading For Global Users Via Solana</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$ONDO

$USDC

Pantera CEO Predicts Surge In Crypto IPOs As US Regulatory Tone Turns Favorable

PicoCELA Inc. ("PicoCELA" or the "Company"), a Tokyo-based provider of enterprise wireless mesh solutions, today announced the pricing of a best-efforts public offering (the "Offering") of 6,100,000 American Depositary Shares ("ADSs") at a public offering price of $0.30 per ADS. The Company expects to receive aggregate gross proceeds of $1,830,000, before deducting placement agent commissions and other offering expenses. Each ADS represents one common share of the Company.
The Offering is expected to close on or about May 27, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use approximately 70% of the net proceeds from the Offering for working capital and general corporate purposes and approximately 30% for product development and research.

PCLA

PicoCELA Prices Best-Efforts Public Offering Of 6.1M ADSs At $0.30 Each, Targeting $1.83M In Gross Proceeds

JP Morgan analyst Tami Zakaria upgrades Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) from Neutral to Overweight and raises the price target from $225 to $277.

Upgrades

Price Target

Analyst Ratings

JP Morgan Upgrades Waste Management to Overweight, Raises Price Target to $277

Data show continuous&nbsp;clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group
Women treated with IMNN-001 and standard of care chemotherapy plus PARP inhibitors achieved nearly 12-month increase in PFS compared to standard of care; median OS in IMNN-001 treatment arm not yet reached after more than five years
Phase 2 OVATION 2 Study results also published in peer-reviewed journal Gynecologic Oncology
LAWRENCEVILLE, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=gjJV-8pq5g3oh1gh2jUxuoxJ0F5LPAG3SU7issIrNRZCETVe_q2IlrAJcaJ5wQ5-9ZsXI4EUNHnps6gnEtaM-VqHf2_SdhwGIezCyprWiKe7JdIggh4sV23Y5iUqugYpLSEcgUXXzzFMYh2cT48PtMnU7hmhss-w0LiVOW6CIhcMXGfJlLqq14KIi5URF4Vmpp321Ua074W-y5CIsq-DCtYrRt1pPPODxGRibgtPD9pWkSMHsOUVo9W9Oq6QMejCDS-SOkTmorkYHd6Qvvcawbs5RAdw2yLVRM83xqb3XSegDpZHVnnhEloZA9JHP9oZnWOZ24q5NuOhA6e4XpE587QHr6nO3mo04hqJGhreX00=">IMUNON</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced new positive data from the Company's Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for the treatment of advanced ovarian cancer. Results are being highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 - June 3, 2025, in Chicago, Illinois and virtually, and are also being published simultaneously in the peer-reviewed journal Gynecologic Oncology.
Based on the highly encouraging Phase 2 OVATION 2 Study results and following alignment with the U.S. Food and Drug Administration (FDA), IMUNON recently initiated the first two sites for its pivotal Phase 3 OVATION 3 Study of IMNN-001 in newly diagnosed advanced ovarian cancer.

IMNN

IMUNON To Present New Data From Phase 2 OVATION 2 Study Of IMNN-001, Investigational Therapy For Treatment Of Advanced Ovarian Cancer At 2025 ASCO Annual Meeting

Acquisition expected to increase Safety Shot annual revenue by 1000 percent over 2024
SCOTTSDALE, Ariz., May 23, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("SHOT", "Safety Shot", or the "Company"), a wellness and dietary supplement company, announces its strategic plans to capitalize on the growth of Yerbae Brands Corp. ("Yerbae") after its recently announced acquisition of the company. With Yerbae's momentum into 2025, Safety Shot expects to leverage the brand's expanding retail presence, strong distributor network, and innovative product portfolio to accelerate growth and strengthen its market position. In addition, the Company anticipates a 1000% increase in 2025 annual revenue over 2024 following the acquisition, bringing significant additional shareholder value.

SHOT

Safety Shot Announces Strategic Plans To Capitalize On Growth Of Yerbae Brands; Acquisition Expected To Increase Safety Shot Annual Revenue By 1000 Percent Over 2024

<h3>Gainers</h3>
<ul>
<li>INNEOVA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INEO#NASDAQ">INEO</a>) shares rose 43.0% to $1.28 during Friday's pre-market session. The market value of their outstanding shares is at $12.6 million. The company's, FY earnings came out 4 days ago. </li>
<li>Lottery.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRY#NASDAQ">LTRY</a>) shares rose 26.24% to $2.02. The company's market cap stands at $25.8 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares moved upwards by 11.7% to $4.2. The market value of their outstanding shares is at $2.4 million. </li>
<li>Jinxin Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMI#NASDAQ">NAMI</a>) stock moved upwards by 9.37% to $3.5. The market value of their outstanding shares is at $239.2 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) shares moved upwards by 8.19% to $0.85. The market value of their outstanding shares is at $8.9 million. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) shares increased by 6.97% to $0.27. The market value of their outstanding shares is at $9.5 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) shares fell 19.0% to $102.15 during Friday's pre-market session. The market value of their outstanding shares is at $15.5 billion. The company's, Q4 earnings came out yesterday. </li>
<li>MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) stock fell 15.28% to $18.8. The company's market cap stands at $5.7 billion. As per the press release, Q1 earnings came out today. </li>
<li>Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) shares fell 12.41% to $133.37. The market value of their outstanding shares is at $43.8 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Volcon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) stock declined by 8.47% to $0.56. The market value of their outstanding shares is at $2.4 million. </li>
<li>Connexa Sports Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) shares declined by 6.18% to $0.76. The market value of their outstanding shares is at $11.0 million. </li>
<li>Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) stock fell 6.11% to $6.77. The market value of their outstanding shares is at $2.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

DECK

ECDA

INEO

LTRY

MNSO

NAMI

PTON

ROST

SBET

VLCN

Connexa Sports Technologies Inc. - Common Stock

YYAI

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares rose 17.3% to $0.95 during Friday's pre-market session. The market value of their outstanding shares is at $38.3 million. </li>
<li>BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) stock moved upwards by 11.21% to $11.6. The market value of their outstanding shares is at $219.0 million. </li>
<li>PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) shares increased by 10.18% to $1.73. The market value of their outstanding shares is at $79.0 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock moved upwards by 10.0% to $1.32. The company's market cap stands at $86.9 million. </li>
<li>Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) shares moved upwards by 9.47% to $6.7. The market value of their outstanding shares is at $361.6 million. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock rose 9.42% to $4.41. The market value of their outstanding shares is at $1.5 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) shares declined by 20.7% to $12.42 during Friday's pre-market session. The market value of their outstanding shares is at $677.3 million. </li>
<li>Immix Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMX#NASDAQ">IMMX</a>) shares fell 16.5% to $2.01. The market value of their outstanding shares is at $56.1 million. </li>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) shares fell 14.64% to $1.4. The market value of their outstanding shares is at $46.9 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares declined by 13.67% to $1.2. The company's market cap stands at $3.0 million. </li>
<li>Turnstone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) shares decreased by 8.31% to $0.31. The company's market cap stands at $7.1 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares decreased by 7.84% to $0.51. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

BCAX

BDRX

BRNS

BWAY

FULC

IMMX

IOBT

OTLK

PDSB

TSBX

12 Health Care Stocks Moving In Friday's Pre-Market Session

JP Morgan analyst Tami Zakaria downgrades GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) from Overweight to Neutral and raises the price target from $51 to $54.

Downgrades

JP Morgan Downgrades GFL Environmental to Neutral, Raises Price Target to $54

<h3>Gainers</h3>
<ul>
<li>Rain Enhancement (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIN#NASDAQ">RAIN</a>) shares rose 26.8% to $5.35 during Friday's pre-market session. The company's market cap stands at $40.5 million. </li>
<li>Agrify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) shares increased by 14.5% to $25.0. The company's market cap stands at $48.8 million. </li>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) shares moved upwards by 14.04% to $3.41. The company's market cap stands at $12.1 million. </li>
<li>FTAI Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIP#NASDAQ">FIP</a>) stock increased by 14.0% to $5.7. The market value of their outstanding shares is at $654.1 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares increased by 7.92% to $0.94. The market value of their outstanding shares is at $16.2 million. </li>
<li>NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) stock increased by 7.46% to $27.21. The market value of their outstanding shares is at $3.6 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) shares declined by 23.2% to $2.55 during Friday's pre-market session. The company's market cap stands at $21.1 million. </li>
<li>Marwynn Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MWYN#NASDAQ">MWYN</a>) shares decreased by 14.92% to $7.7. The market value of their outstanding shares is at $131.3 million. </li>
<li>Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) shares decreased by 11.51% to $114.28. The market value of their outstanding shares is at $14.1 billion. The company's, Q4 earnings came out today. </li>
<li>Nocera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCRA#NASDAQ">NCRA</a>) stock declined by 10.66% to $0.89. The market value of their outstanding shares is at $12.7 million. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) stock fell 8.86% to $0.51. The market value of their outstanding shares is at $3.6 million. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares decreased by 7.02% to $0.73. The company's market cap stands at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGFY

MWYN

NCRA

RAIN

SGBX

VCIG

XPON

ZBAI

12 Industrials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Sagtec Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) stock moved upwards by 19.8% to $3.87 during Friday's pre-market session. The company's market cap stands at $48.5 million. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) shares increased by 14.2% to $3.94. The company's market cap stands at $5.2 million. </li>
<li>Semilux International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELX#NASDAQ">SELX</a>) shares moved upwards by 11.91% to $1.68. The market value of their outstanding shares is at $62.8 million. </li>
<li>Saiheat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIH#NASDAQ">SAIH</a>) stock moved upwards by 11.3% to $6.3. The market value of their outstanding shares is at $10.6 million. </li>
<li>SmartRent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) stock moved upwards by 8.3% to $0.88. The market value of their outstanding shares is at $165.9 million. </li>
<li>Diginex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) stock increased by 7.76% to $69.82. The market value of their outstanding shares is at $1.6 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) shares decreased by 14.2% to $4.83 during Friday's pre-market session. The company's market cap stands at $640.0 million. </li>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) shares declined by 9.68% to $0.56. The market value of their outstanding shares is at $3.9 million. </li>
<li>Xerox Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) stock fell 9.41% to $4.64. The market value of their outstanding shares is at $583.4 million. </li>
<li>Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) stock decreased by 8.45% to $249.1. The company's market cap stands at $66.6 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Mercurity Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) shares fell 7.79% to $4.5. The market value of their outstanding shares is at $286.5 million. </li>
<li>Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares decreased by 7.72% to $4.66. The market value of their outstanding shares is at $893.8 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIOT

DGNX

MOVE

NVTS

OBLG

SAGT

SAIH

SELX

SMRT

WDAY

12 Information Technology Stocks Moving In Friday's Pre-Market Session

Multi Ways Holdings Limited ("Multi Ways", the "Company" or the "Issuer") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MWG#NYSE">MWG</a>), a leading supplier of a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region, today announced the receipt of notification (the "Filing Deficiency Notification") from New York Stock Exchange Regulation ("NYSE Regulation") on May 16, 2025, indicating that, as a result of not having timely filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024 (the "2024 Form 20-F", or the "Delinquent Report") with the U.S. Securities and Exchange Commission (the "SEC") (the "Filing Delinquency"), the Company is not in compliance with NYSE American LLC ("NYSE American", or the "Exchange") continued listing standards. As a result, the Company is now subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide (the "Company Guide").

Multi Ways Holdings Receives NYSE Deficiency Notice Over Delayed 2024 Form 20-F Filing

JP Morgan analyst Guilherme Mendes upgrades Grupo Aeroportuario del (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAC#NYSE">PAC</a>) from Underweight to Neutral.

JP Morgan Upgrades Grupo Aeroportuario del to Neutral

Ashford Hospitality Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHT#NYSE">AHT</a>) ("Ashford Trust" or the "Company") announced today that it has signed a definitive agreement to sell the 242-room Hilton Houston NASA Clear Lake located in Houston, Texas for $27.0 million. The sale is expected to be completed in June 2025 and is subject to normal closing conditions. The Company provides no assurances that the sale will be completed on these terms or at all.
When adjusted for the Company's anticipated capital expenditures, the sale price represents a 3.2% capitalization rate on net operating income or 23.6x Hotel EBITDA for the twelve months ended April 30, 2025. Excluding the anticipated capital spend, the sale price represents a 5.0% capitalization rate on net operating income or 15.2x Hotel EBITDA for the twelve months ended April 30, 2025.
"We are pleased to announce the signed agreement to sell the Hilton Houston NASA Clear Lake at a very attractive cap rate," commented Stephen Zsigray, Ashford Trust's President and Chief Executive Officer. "This sale will deleverage our Morgan Stanley 17 Pool loan, and result in significant capital expenditure savings. Combined with our "GRO AHT" initiative, we're excited about the potential for opportunistic sales to further transform the company and have additional assets in the market at various stages of the sales process."

Contracts

Asset Sales

Ashford Hospitality Trust Announces It Has Signed A Definitive Agreement To Sell Hilton Houston NASA Clear Lake Located In Houston, Texas For $27M

– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –
– Decision from European Commission expected in the third quarter of 2025 –
STAMFORD, Conn., May 23, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for mirdametinib, a MEK inhibitor, for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients with neurofibromatosis type 1 (NF1) aged 2 years and above. The European Commission (EC) will review the CHMP opinion and is expected to make a final decision regarding the approval in the third quarter of 2025. If approved, mirdametinib will be available in 1 and 2 mg capsules and in a 1 mg dispersible tablet, which dissolves easily in water.

SWTX

SpringWorks Therapeutics Secures EMA CHMP Endorsement For Conditional Approval Of Mirdametinib In NF1-PN Treatment

The Mining Association of Canada (MAC) released a comprehensive report evaluating the sector's role in the <a target="_blank" href="https://www.benzinga.com/topic/canada" rel="noreferrer noopener">country's economy</a> and providing an outlook.
The <a target="_blank" href="https://mining.ca/wp-content/uploads/dlm_uploads/2025/05/MAC-Report_2025-final-1.pdf" rel="noreferrer noopener">report</a>, titled The Mining Story—Canadian Mining Industry Facts and Figures, sets the total value of mineral production at C$71.9 billion ($52 billion). The total GDP contribution was C$117 billion ($84.7 billion), around 4% of the national GDP.
"These numbers show the wealth that could come to Canada if we develop our mineral endowment," said MAC CEO Pierre Gratton. When mining, quarrying and oil and gas extraction are included, the share of GDP rises to 5.1%.
Employment figures remained strong, with 430,000 direct jobs and 281,000 indirect ones, demonstrating the sector's high-quality employment footprint. However, Gratton cautioned against complacency. "Geopolitical challenges, national security concerns, the transition to a low-carbon economy and the basic need to build and sustain a strong economy in the face of tariffs will require far more mined materials than we currently produce," he said.
Gold and copper stood out as key minerals. Gold surpassed passenger vehicles as Canada's second-largest export, reaching a value of C$30.2 billion ($21.87 billion) and representing 4.6% of all merchandise exports. Its role as a safe haven asset during times of uncertainty boosted demand and helped Canada become a leading exporter.
Copper, whose cornerstone role in green energy technologies has been increasing, brought in C$38.9 billion ($28.17 billion). Production, which amounted to around 508,000 tons, is still historically low compared to highs from 2016, when production exceeded 650,000 tons.
Gratton clarified that Canada must improve investment conditions and streamline regulatory frameworks to accelerate mine development.
"To supply the resources that are needed, Canada must foster a more efficient investment and regulatory environment," he said, calling for better federal-provincial coordination, faster permitting, and enhanced Indigenous consultation to ensure mining projects are developed in a timely but responsible manner.
This push for regulatory efficiency has gained momentum in Ontario, where Premier Doug Ford's government introduced Bill 5, the Protect Ontario by Unleashing our Economy Act. Framed as a tool to cut through what Ford describes as "a maze of bureaucracy," the bill would enable the province to fast-track mining approvals by establishing special economic zones exempt from certain environmental regulations.
The Ford government argues that these reforms are critical to unlocking mineral wealth in areas like the Ring of Fire and improving Ontario's global competitiveness in mine development timelines. Critics, however, say the legislation reduces oversight too far.
"They're just using this as a pretext for doing what they wanted to do already and hoping that people won't notice that the two are not really connected," Jamie Kneen, co-founder of MiningWatch Canada, said, <a target="_blank" href="https://www.cbc.ca/news/canada/toronto/ontario-mining-bill-5-legislation-faster-approvals-1.7539045" rel="noreferrer noopener">per</a> CBC.
Despite claims that the bill will shorten approval timelines from four years to two, Keen said that economic factors—not just regulation—are often responsible for delays in mine development. He pointed out Generation Mining's (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/GENMF#OTCQB">GENMF</a>) Marathon copper-palladium project, which paused for six years due to low prices. The mine was approved in 2022 but has yet to begin construction.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/rumors/25/05/45562268/dundee-precious-metals-eyes-adriatic-metals-for-935-million-no-formal-offer-yet" target="_blank" rel="noreferrer noopener">Dundee Precious Metals Eyes Adriatic Metals For $935 Million, No Formal Offer Yet</a></li>
</ul>
Photo by TimBrew via Shutterstock

Government

Regulations

Guidance

Commodities

Markets

COPX

CPER

GENMF

GLDM

SGOL

Gold, Copper Drive Canadian Mining As Industry Pushes For Reforms

JP Morgan analyst Guilherme Mendes downgrades Central North Airport Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMAB#NASDAQ">OMAB</a>) from Neutral to Underweight.

Grupo Aeroportuario del Centro NorteB de CV

OMAB

JP Morgan Downgrades Central North Airport Gr to Underweight

WIIM

Gold is trading higher after President Trump recommended a 50% straight tariff on the European Union, staring Jun. 1.

Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) underwent analysis by 22 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Best Buy Co, presenting an average target of $90.0, a high estimate of $110.00, and a low estimate of $64.00. Experiencing a 9.71% decline, the current average is now lower than the previous average price target of $99.68. 
<img src="https://www.benzinga.com/files/images/story/2025/1748001697_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Best Buy Co's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$64.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$81.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$93.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$80.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Steven Forbes</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Elizabeth Suzuki</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jonathan Matuszewski</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$92.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Best Buy Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Best Buy Co compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Best Buy Co's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Best Buy Co's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BBY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Best Buy Co analyst ratings.</a>
<h2>Delving into Best Buy Co's Background</h2>
With $41.5 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
<h3>Best Buy Co's Economic Impact: An Analysis</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Best Buy Co's revenue growth over a period of 3M has faced challenges. As of 31 January, 2025, the company experienced a revenue decline of approximately -4.77%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Best Buy Co's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 0.84%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Best Buy Co's ROE stands out, surpassing industry averages. With an impressive ROE of 3.97%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Best Buy Co's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.74%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Best Buy Co's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.44, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Best Buy Co In The Eyes Of 22 Experts

Ratings for Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $19.22, a high estimate of $21.00, and a low estimate of $15.00. This current average reflects an increase of 3.56% from the previous average price target of $18.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1748001685_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Arcutis Biotherapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Kambiz Yazdi</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Arcutis Biotherapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Arcutis Biotherapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Arcutis Biotherapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Arcutis Biotherapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARQT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Arcutis Biotherapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Arcutis Biotherapeutics</h2>
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
<h3>Arcutis Biotherapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Arcutis Biotherapeutics showcased positive performance, achieving a revenue growth rate of 32.84% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Arcutis Biotherapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -38.06%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Arcutis Biotherapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -16.7%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Arcutis Biotherapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.23%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Arcutis Biotherapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.78, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARQT

Analyst Expectations For Arcutis Biotherapeutics's Future

Analysts' ratings for Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) over the last quarter vary from bullish to bearish, as provided by 13 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Intuit, revealing an average target of $717.08, a high estimate of $825.00, and a low estimate of $600.00. This current average represents a 0.8% decrease from the previous average price target of $722.85. 
<img src="https://www.benzinga.com/files/images/story/2025/1748001672_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Intuit among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$825.00</td>
<td>$785.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$720.00</td>
<td>$655.00</td>
</tr>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$700.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$720.00</td>
<td>$730.00</td>
</tr>
<tr>
<td>Scott Schneeberger</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$642.00</td>
<td>$722.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$735.00</td>
<td>$800.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$660.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$765.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$600.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$726.00</td>
<td>$760.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$714.00</td>
<td>$760.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$730.00</td>
<td>$730.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$785.00</td>
<td>$765.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Intuit. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Intuit compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Intuit's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Intuit's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/INTU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intuit analyst ratings.</a>
<h2>Unveiling the Story Behind Intuit</h2>
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small business accounting and do-it-yourself tax filing in the US.
<h3>Financial Milestones: Intuit's Journey</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Intuit's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.04% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 11.88%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Intuit's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.61%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.45%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Intuit adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTU

Intuit Stock: A Deep Dive Into Analyst Perspectives (13 Ratings)

Press Releases

CBD Life Sciences Inc. (CBDL) Announces Its Official Launch on Groupon.com

CBDL Launches New Mushroom Supplement Drink & Smoothie Bar

CBD Life Sciences Inc. (CBDL) Launches Mushroom Powder Capsules

CBD Life Sciences Inc. (CBDL) Gears Up for Cave Creek Bike Week 2025

CBD Life Sciences Inc. (CBDL) Launches Passion Fuel Cordyceps Complex - A Powerful Sexual Enhancement Supplement

CBD Life Sciences Inc. (CBDL) Powers Forward with Disruptive Brain-Boosting Mushroom Applications

CBD Life Sciences Inc. (CBDL) Company Online Sales Up 500%

CBD Life Sciences Inc. (CBDL) Announces Groundbreaking 100MG Full Spectrum CBD Gummy Geared Toward Mental Health & Focus

CBD Life Sciences Inc. (CBDL) Announces New Manufacturing Deal With A Columbian Company

CBD Life Sciences Inc. (CBDL) Announces New Manufacturing Deal With A Southwest-Based Company

CBDL

CBD Life Sciences

Comments

CBD Life Sciences

Notizie

Ultime notizie per CBD Life Sciences (OTC:CBDL) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO